CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Stock Forecast

Stock Price Forecast

The 17 analysts that cover CRISPR Therapeutics AG stock have a consensus rating of "Buy" and an average price target of $70.29, which forecasts a 35.02% increase in the stock price over the next year. The lowest target is $44 and the highest is $110.

Price Target: $70.29 (+35.02%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$44	$70.29	$76	$110
Change	-15.48%	+35.02%	+45.99%	+111.29%

* Price targets were last updated on Mar 17, 2026.

Analyst Ratings

The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	7	7	7	6	6	6
Buy	4	4	5	5	5	5
Hold	7	7	7	7	6	6
Sell	1	1	1	0	0	0
Strong Sell	0	0	0	0	0	0
Total	19	19	20	18	17	17

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $105 → $110	Buy	Reiterates	$105 → $110	+111.29%	Mar 17, 2026
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $74 → $76	Strong Buy	Maintains	$74 → $76	+45.99%	Feb 17, 2026
Tyler Van Buren TD Cowen	TD Cowen	Hold Maintains $40 → $45	Hold	Maintains	$40 → $45	-13.56%	Feb 13, 2026
Liisa Bayko Evercore ISI Group	Evercore ISI Group	Buy Maintains $62 → $74	Buy	Maintains	$62 → $74	+42.14%	Feb 13, 2026
Gil Blum Needham	Needham	Strong Buy Maintains $80 → $82	Strong Buy	Maintains	$80 → $82	+57.51%	Feb 13, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

31.86M

Increased by 807.72%

from 3.51M

Revenue Next Year

86.83M

Increased by 172.52%

from 31.86M

EPS This Year

-5.02

from -6.47

EPS Next Year

-4.15

from -5.02

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	914.96M	1.20M	371.21M	37.31M	3.51M	31.86M	86.83M
Revenue Growth	127,154.94%	-99.87%	30,885.48%	-89.95%	-90.59%	807.72%	172.52%
EPS	4.70	-8.36	-1.94	-4.34	-6.47	-5.02	-4.15
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	30	26

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030	2031	2032	2033
High	106.1M	264.1M
Avg	31.9M	86.8M
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	2,921.4%	728.9%
Avg	807.7%	172.5%
Low	-	-

EPS Forecast

EPS	2026	2027	2028	2029	2030	2031	2032	2033
High	-2.42	-0.65
Avg	-5.02	-4.15
Low	-6.70	-6.75

EPS Growth

EPS Growth	2026	2027	2028	2029	2030	2031	2032	2033
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.